NASDAQ:MRVI Maravai LifeSciences (MRVI) Stock Price, News & Analysis $9.16 +0.65 (+7.64%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$8.58▼$9.1950-Day Range$6.84▼$11.3452-Week Range$4.52▼$12.10Volume1.26 million shsAverage Volume2.36 million shsMarket Capitalization$2.31 billionP/E RatioN/ADividend YieldN/APrice Target$11.44 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Maravai LifeSciences alerts: Email Address Maravai LifeSciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.70 Rating ScoreUpside/Downside24.9% Upside$11.44 Price TargetShort InterestBearish7.37% of Float Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment0.89Based on 7 Articles This WeekInsider TradingSelling Shares$97.52 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.15) to ($0.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.51 out of 5 starsMedical Sector196th out of 936 stocksPharmaceutical Preparations Industry81st out of 436 stocks 2.4 Analyst's Opinion Consensus RatingMaravai LifeSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageMaravai LifeSciences has only been the subject of 2 research reports in the past 90 days.Read more about Maravai LifeSciences' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.37% of the float of Maravai LifeSciences has been sold short.Short Interest Ratio / Days to CoverMaravai LifeSciences has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Maravai LifeSciences has recently increased by 17.30%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMaravai LifeSciences does not currently pay a dividend.Dividend GrowthMaravai LifeSciences does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMaravai LifeSciences has received a 67.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Deoxyribonucleic acid (DNA)", "Microbiology laboratory services for research", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Maravai LifeSciences is -1.23. Previous Next 3.3 News and Social Media Coverage News SentimentMaravai LifeSciences has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Maravai LifeSciences this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for MRVI on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows3 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Maravai LifeSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $97,520,955.00 in company stock.Percentage Held by InsidersOnly 0.63% of the stock of Maravai LifeSciences is held by insiders.Percentage Held by Institutions50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Maravai LifeSciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.15) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maravai LifeSciences is -9.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Maravai LifeSciences is -9.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaravai LifeSciences has a P/B Ratio of 2.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Maravai LifeSciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Maravai LifeSciences Stock (NASDAQ:MRVI)Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.Read More MRVI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRVI Stock News HeadlinesJuly 25 at 2:10 AM | americanbankingnews.comStock Traders Buy Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI)July 20, 2024 | americanbankingnews.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.July 12, 2024 | seekingalpha.comMaravai: Embedded Expectations Remain Too High Considering Economic CalculusJuly 12, 2024 | seekingalpha.comMaravai: Embedded Expectations Remain Too High Considering Economic CalculusJuly 10, 2024 | globenewswire.comMaravai LifeSciences To Host Earnings Conference Call on Wednesday, August 7, 2024July 2, 2024 | globenewswire.comMaravai Lifesciences Releases 2023 Environmental, Social and Governance (ESG) ReportJune 11, 2024 | seekingalpha.comRGA Investment Advisors - Maravai: Two Elite Assets With Other-Worldly Margins Wrapped In OneJuly 26, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.May 29, 2024 | msn.comSemler Scientific, Genetic Technologies, ReShape Lifesciences among healthcare moversMay 29, 2024 | benzinga.comWhy Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionMay 29, 2024 | marketwatch.comMaravai LifeSciences Shares Fall 16% After Stock-Sale ProposalsMay 19, 2024 | finance.yahoo.comMaravai LifeSciences Holdings, Inc. (MRVI)May 13, 2024 | businesswire.comTriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation CenterMay 10, 2024 | finance.yahoo.comMaravai LifeSciences Holdings First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 9, 2024 | finance.yahoo.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q1 2024 Earnings Call TranscriptMay 9, 2024 | globenewswire.comMaravai LifeSciences Announces May and June 2024 Investor Conference ScheduleMay 9, 2024 | finance.yahoo.comMaravai LifeSciences Holdings Inc (MRVI) (Q1 2024) Earnings Call Transcript Highlights:See More Headlines Receive MRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Confirmed)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRVI CUSIPN/A CIK1823239 Webwww.maravai.com Phone858-546-0004FaxN/AEmployees650Year FoundedN/APrice Target and Rating Average Stock Price Target$11.44 High Stock Price Target$17.00 Low Stock Price Target$7.00 Potential Upside/Downside+28.9%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,030,000.00 Net Margins-47.81% Pretax Margin218.84% Return on Equity-4.28% Return on Assets-1.92% Debt Debt-to-Equity Ratio0.71 Current Ratio11.32 Quick Ratio10.47 Sales & Book Value Annual Sales$288.95 million Price / Sales7.74 Cash Flow$0.10 per share Price / Cash Flow87.43 Book Value$3.14 per share Price / Book2.83Miscellaneous Outstanding Shares251,930,000Free Float250,338,000Market Cap$2.24 billion OptionableOptionable Beta0.02 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Carl W. Hull (Age 65)Co-Founder & Executive Chairman Comp: $617.67kMr. William E. Martin III (Age 49)Chief Executive Officer Comp: $987.86kMr. Kevin M. Herde (Age 52)Executive VP & CFO Comp: $548.62kDr. Peter Michael Leddy Ph.D. (Age 61)Executive VP & Chief Administrative Officer Comp: $583.39kMs. Christine Dolan (Age 56)Executive VP & GM of Cygnus Technologies Comp: $536.63kMr. Andrew Burch (Age 55)President of Nucleic Acid Production Comp: $425.15kMs. Debra HartSenior Director of Investor RelationsMr. Kurt Oreshack (Age 43)Executive VP, General Counsel & Secretary Comp: $701.4kMs. Rebecca BuzzeoExecutive VP & Chief Commercial OfficerDr. Kate E. Broderick Ph.D.Chief Innovation OfficerMore ExecutivesKey CompetitorsIntra-Cellular TherapiesNASDAQ:ITCIRoivant SciencesNASDAQ:ROIVCerevel TherapeuticsNASDAQ:CEREAscendis Pharma A/SNASDAQ:ASNDIonis PharmaceuticalsNASDAQ:IONSView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 117,120 shares on 7/26/2024Ownership: 0.201%Liontrust Investment Partners LLPBought 5,628 shares on 7/26/2024Ownership: 0.017%Blue Trust Inc.Bought 6,194 shares on 7/18/2024Ownership: 0.002%Wedmont Private CapitalSold 3,932 shares on 7/16/2024Ownership: 0.015%Simplicity Wealth LLCSold 6,482 shares on 7/10/2024Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions MRVI Stock Analysis - Frequently Asked Questions How have MRVI shares performed this year? Maravai LifeSciences' stock was trading at $6.55 at the beginning of the year. Since then, MRVI shares have increased by 39.8% and is now trading at $9.16. View the best growth stocks for 2024 here. How were Maravai LifeSciences' earnings last quarter? Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) announced its earnings results on Wednesday, May, 8th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.05. The firm earned $64.18 million during the quarter, compared to analyst estimates of $60.84 million. Maravai LifeSciences had a negative net margin of 47.81% and a negative trailing twelve-month return on equity of 4.28%. When did Maravai LifeSciences IPO? Maravai LifeSciences (MRVI) raised $1.3 billion in an initial public offering on Friday, November 20th 2020. The company issued 50,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers. Who are Maravai LifeSciences' major shareholders? Maravai LifeSciences' top institutional investors include Bank of New York Mellon Corp (0.20%), Liontrust Investment Partners LLP (0.02%), Wedmont Private Capital (0.02%) and Simplicity Wealth LLC (0.01%). View institutional ownership trends. How do I buy shares of Maravai LifeSciences? Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRVI) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
